You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南京新百(600682.SH):子公司上海丹瑞生物首次獲得藥品生產許可證
格隆匯 07-29 18:06

格隆匯 7 月 29日丨南京新百(600682.SH)公佈,公司控股子公司上海丹瑞生物醫藥科技有限公司(“上海丹瑞生物)於近日獲得了上海市藥品監督管理局頒發的《藥品生產許可證》。

生產地址和生產範圍:中國(上海)自由貿易試驗區哥白尼路1502幢一、二層;治療用生物製品(上市前註冊階段)

次是控股子公司上海丹瑞生物首次獲得《藥品生產許可證》,為美國Dendreon Pharmaceuticals LLC.Sipuleucel-T細胞注射液(商品名Provenge)在中國境內(不包括港澳台地區,下同)進行本地化生產的實現具有積極意義。

截至公告日,Provenge仍為全球唯一用於治療前列腺癌的已上市細胞免疫治療藥物,中國境內尚無同類藥物獲批上市。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account